Newer agents in antiplatelet therapy: a review.

Jennifer Yeung  
*Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University,*  
Jennifer.Yeung@jefferson.edu

Michael Holinstat  
*Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University,*  
michael.holinstat@jefferson.edu

Let us know how access to this document benefits you

Follow this and additional works at: [http://jdc.jefferson.edu/cardeza_foundation](http://jdc.jefferson.edu/cardeza_foundation)

Part of the [Hematology Commons](http://jdc.jefferson.edu/cardeza_foundation)

Recommended Citation

*Cardeza Foundation for Hematologic Research.* Paper 2.  
[http://jdc.jefferson.edu/cardeza_foundation/2](http://jdc.jefferson.edu/cardeza_foundation/2)
Abstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although there has been significant advancement in antiplatelet therapeutic approaches, aspirin still remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies. The pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number of antiplatelet inhibitors currently in use due to variability in metabolism, time to onset, and reversibility. A focused effort in the development of newer antiplatelet therapies to address some of these shortcomings has resulted in a significant number of potential antiplatelet drugs which target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, prostaglandins, protease-activated receptors, thromboxane), and glycoproteins (αIIbβ3, GPVI, vWF, GPIb) in the platelet. The validation and search for newer antiplatelet therapeutic approaches proven to be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with fewer untoward side-effects to what is currently in use today.

Keywords: platelet aggregation inhibitors, blood platelets, purinergic P2Y receptor antagonists, receptor, PAR-1, platelet glycoprotein GPIIb-IIIa, thrombosis

Introduction

Antiplatelet drugs are the cornerstone in treatment of cardiovascular diseases. Despite the significant decrease in morbidity and mortality due to the currently approved antiplatelet drugs, recurrent ischemia, myocardial infarction (MI), and unwanted bleeding still occur. The majority of drugs in development have focused on targeting either surface receptors or enzymes in the platelet in order to protect against unwanted clot formation following initial platelet activation. The first target for antiplatelet therapy was cyclooxygenase-1 by aspirin. While newer approaches for containing platelet activity have been developed, the pharmacodynamics and pharmacoeconomics suggest that aspirin will continue to be a mainstay for platelet therapy in the years to come. Currently, a combination regimen of aspirin and clopidogrel is the standard of care for prevention of platelet activation, thrombosis, and stroke. Unfortunately many of the current antiplatelet drugs face limitations in their utility due to genetic differences in the ability to metabolize pro-drugs, such as is the case with clopidogrel, acquired allergic responses such as is seen with heparin and aspirin, and resistance as has been reported with aspirin (see Table 1). Additional limitations observed in the application...
of currently approved antiplatelet drugs include a narrow therapeutic window and limited efficacy. An overview of the current Food and Drug Administration (FDA)-approved antiplatelet therapies as well as those in development will be discussed in this review.

**P2Y receptor antagonists**

The P2Y receptors are G-protein-coupled (GPCR) purinergic receptors belonging to the P2 family. Two receptors, P2Y1 and P2Y12, are present in the platelet. P2Y1 is a Gq coupled GPCR, while P2Y12 is coupled to Gαq. Activation of P2Y1 signals phospholipase β, leading to DAG formation, calcium mobilization, and eventually PKC and CalDAG-GEF activation.1 In contrast, P2Y12 activation inhibits adenylyl cyclase, activates phosphoinositide 3-kinase,2 the small GTPase Rap1,3 and activation of αIIbβ3.4

Ticlopidine (Ticlid®, Roche, Basel, Switzerland) is a first generation thienopyridine that requires cytochrome P450 (CYP) 1A metabolism prior to exerting its irreversible antagonistic effects on platelet reactivity via the P2Y12 receptor.5 Early experimental observations showed agonist-induced platelet aggregation was intermittently inhibited by ticlopidine.6–7 Studies with ticlopidine, however, exhibit off-target effects mediated by the inhibition of intracellular calcium mobilization.8 Maximal inhibition of platelet aggregation is observed 3–5 days post administration of ticlopidine.9 The delayed onset of antiplatelet effects is a consequence of metabolism of the pro-drug.6 Clinical trials (CATS and TASS studies) have shown ticlopidine to be more effective than aspirin alone,10,11 but exhibiting significant off-target effects including minor bleeding with hemorrhagic events observed in less than 1% of subjects studied. Additionally, ticlopidine-treated patients typically discontinue treatment due to a variety of secondary adverse events including diarrhea, skin rash, and neutropenia.10,12

Clopidogrel (Plavix®, Bristol-Myers Squibb, New York City, NY), a second generation oral thienopyridine, also requires metabolism of the pro-drug by the CYP2C19. The active metabolite, which is a highly labile compound, irreversibly binds to and inhibits the P2Y12 receptor through a disulfide bridge. The CURE trial has shown the clinical benefit of the dual clopidogrel-aspirin therapy compared with aspirin alone by significantly reducing mortality and nonfatal MI or stroke in patients with unstable angina; however, the dual regimen was associated with an increase in bleeding compared with placebo.13,14 The CAPRIE trial, which evaluated the efficacy of clopidogrel monotherapy compared with dual therapy of clopidogrel plus aspirin, showed clopidogrel treatment results in a reduction of primary endpoints.15 Evidence of poor metabolizers for clopidogrel has helped to explain the reduced function in patients with an altered CYP2C19 allele.16 Poor metabolizers of clopidogrel have diminished platelet inhibition resulting in a higher rate of adverse cardiovascular events than noncarriers.17

**Table 1** Approved antiplatelet drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target</th>
<th>Half-life</th>
<th>Side effects</th>
<th>Bioavailability</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticlopidine (Ticlid)</td>
<td>P2Y12 receptor</td>
<td>12 hours</td>
<td>Bleeding, rash, neutropenia, thrombotic thrombocytopenic purpura (rare), nausea, vomiting, heartburn, indigestion</td>
<td>Oral</td>
<td>Transient ischemic attacks, patients undergoing PCI</td>
</tr>
<tr>
<td>Clopidogrel (Plavix)</td>
<td>P2Y12 receptor</td>
<td>6–8 hours</td>
<td>Bleeding, rash, neutropenia, thrombotic thrombocytopenic purpura (rare)</td>
<td>Oral</td>
<td>NSTEMI, STEMI, PCI, recent stroke, or established PAD</td>
</tr>
<tr>
<td>Prasugrel (Effient)</td>
<td>P2Y12 receptor</td>
<td>8 hours</td>
<td>Bleeding</td>
<td>Oral</td>
<td>Patients with ACS undergoing PCI</td>
</tr>
<tr>
<td>Ticagrelor (Brilinta)</td>
<td>P2Y12 receptor</td>
<td>6–12 hours</td>
<td>Dyspnea</td>
<td>Oral</td>
<td>STEMI, ACS</td>
</tr>
<tr>
<td>Abciximab (ReoPro)</td>
<td>GPIIb-IIIa</td>
<td>&lt;10–30 minutes</td>
<td>Bleeding, thrombocytopenia, EDTA-induced pseudothrombocytopenia</td>
<td>IV</td>
<td>PCI</td>
</tr>
<tr>
<td>Eptifibatide (Integrilin)</td>
<td>GPIIb-IIIa</td>
<td>–2.5 hours</td>
<td>Bleeding, thrombocytopenia, EDTA-induced pseudothrombocytopenia</td>
<td>IV</td>
<td>NSTEMI, PCI, unstable angina</td>
</tr>
<tr>
<td>Tirofiban (Aggrastat)</td>
<td>GPIIb-IIIa</td>
<td>2 hours</td>
<td>Bleeding, thrombocytopenia, EDTA-induced pseudothrombocytopenia</td>
<td>IV</td>
<td>NSTEMI, PCI, unstable angina</td>
</tr>
<tr>
<td>Cilostazol (Pletal)</td>
<td>PDE3</td>
<td>11–13 hours</td>
<td>Headache, dizziness, hypotension, flushing, nausea, vomiting, diarrhea, abdominal pain</td>
<td>Oral</td>
<td>Intermittent claudication, PAD, PCI</td>
</tr>
<tr>
<td>Dipyridamole (Aggrenox)</td>
<td>PDE3 and inhibition of adenosine uptake</td>
<td>10 hours</td>
<td>Bleeding, headache, diarrhea, palpitations, dizziness, rash, pancytopenia</td>
<td>Oral</td>
<td>Transient ischemic attacks</td>
</tr>
</tbody>
</table>

Abbreviations: ACS, acute coronary syndromes; EDTA, ethylenediaminetetraacetic acid; GP, glycoprotein; IV, intravenous; NSTEMI, non-ST elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PDE, phosphodiesterase; STEMI, ST elevation myocardial infarction.
Prasugrel (Effient®, Eli Lilly and Company, Indianapolis, IN) is a third-generation thienopyridine, chemically distinct from clopidogrel. In-vivo and in-vitro pharmacological studies have demonstrated that this adenosine triphosphate (ATP) analog selectively and irreversibly inhibits adenosine diphosphate (ADP)-induced aggregation to a greater degree than clopidogrel. The irreversible binding is thought to be due to the disulfide binding between the reactive thiol group of the active metabolite and the cysteine residue of the P2Y$_{12}$ receptor. Prasugrel is an orally available pro-drug that requires active transformation via the CYP450 along with esterases. Activation of the pro-drug requires CYP3 A4 and CYP2B6. Clinical studies have verified that inhibition of platelet aggregation is more effective with prasugrel compared with clopidogrel after a single dose in healthy subjects. Furthermore, subjects who responded poorly to clopidogrel showed greater platelet-induced inhibition in response to prasugrel. Further, assessment of secondary endpoints favors prasugrel due to lower incidences of cardiovascular death, nonfatal MI, and rehospitalization due to recurrent ischemia.

Ticagrelor (Brillinta®, AstraZeneca, London, UK), an oral cyclooctyl-triazolo-pyrimidine analog, unlike thienopyridines, is a direct and reversible inhibitor of the P2Y$_{12}$ receptor that is activated from its pro-drug by CYP3 A. Ticagrelor exerts its action via binding to the P2Y$_{12}$ receptor at a site distinct from the ADP binding site, thus making it an allosteric inhibitor. As a consequence of P2Y$_{12}$ inhibition, ATP is converted to cyclic monophosphate, vasodilator-stimulated phosphoprotein is dephosphorylated, and activation of PI3-K is inhibited. The PLATO trial compared ticagrelor with clopidogrel in which the primary composite endpoints, stroke, MI, cardiovascular death, and stent thrombosis, were reduced in patients with acute coronary syndromes (ACS) (with or without ST-elevation MI). The benefit of ticagrelor appears to be attenuated in patients with lower bodyweight and those not taking lipid-lowering drugs in North American groups relative to comparative studies elsewhere. There is no significant difference in major bleeding between the two agents; however, spontaneous (noncoronary artery bypass grafts) or nonprocedural-related bleeding is increased with ticagrelor. Additionally, off-target effects of dyspnea and asymptomatic ventricular pauses are associated with ticagrelor use. In general, ticagrelor has so far proven superior to current treatment regimens, including a rapid onset of action, acceptable safety profile, and effectiveness in reducing the primary endpoints in ACS patients.

Elinogrel (PRT060128, Novartis, Basel, Switzerland/Portola Pharmaceuticals, South San Francisco, CA) is a direct-acting reversible P2Y$_{12}$ receptor inhibitor that is currently undergoing clinical investigation (INNOVATE-PCI) for efficacy and safety in patients undergoing percutaneous coronary intervention (PCI) (see Table 2). Preclinical data show that intravenous or orally administered elinogrel is superior to clopidogrel and has minimal effect on bleeding times. In addition, a single dose of elinogrel has been shown to overcome high platelet reactivity in patients undergoing PCI who were nonresponsive to clopidogrel. Elinogrel, while still in clinical development for safety and efficacy assessment in patients, shows promise as a next generation P2Y$_{12}$ antagonist.

Cangrelor (ARC-69931MX, The Medicines Company, Parsippany, NJ) is an intravenous nonthienopyridine and reversible P2Y$_{12}$ inhibitor. Like prasugrel and ticagrelor, cangrelor showed a more rapid onset of action and greater degree of platelet inhibition than clopidogrel. Recent evaluations of the inhibitor in the CHAMPION-PCI and CHAMPION-PLATFORM trials were stopped early due to its lack of apparent differences in the primary endpoint of death, MI, or ischemia-driven revascularization 48 hours after PCI. Also, the rate of major bleeding in patients undergoing PCI was higher with cangrelor compared with clopidogrel in both studies.

Table 2. Antiplatelet drugs under development.
BX 667 is an orally active reversible P2Y₁₂ receptor antagonist that is metabolized by esterases to form the carboxylic active form, BX 048. In-vitro, ADP-induced aggregation is potently inhibited by BX 667. Additionally, administration of BX 667 results in a rapid and sustained inhibition aggregation. This observation is also supported by the intravenous BX 048 and oral BX 667 administration in rat arteriovenous-shunt model which showed a similar pharmacodynamic relationship between the plasma concentration of BX 048 and thrombus inhibition. This antagonist has yet to be evaluated in healthy human subjects.

**Glycoprotein antagonists αIIbβ3 antagonists**

Glycoprotein GPIIbIIIa (αIIbβ3) is the most abundant integrin on the platelet surface. αIIbβ3 is known to be involved in both inside-out or outside-in platelet signaling. The inside-out signaling in platelet activation involves the various signaling pathways that converge into a common signaling endpoint that leads to the activation of integrin αIIbβ3. Ligand binding of fibrinogen or von Willebrand factor (VWF) to αIIbβ3 mediates platelet adhesion and aggregation, triggers outside-in integrin activation and results in additional granule secretion, stabilization of platelet adhesion, aggregation, and clot retraction.

Abciximab (ReoPro®; Eli Lilly) is an antibody developed from the murine human chimera c7E3 Fab, which targets the integrin αIIbβ3, preventing integrin binding to fibrinogen and VWF. Abciximab rapidly binds with high affinity and has a slow rate of dissociation from its target. In addition, abciximab binds with high affinity to α₃ (vitronectin receptor) and low affinity to the leukocyte MAC-1 receptor. Initial intravenous administration enables rapid onset of platelet inhibition. As abciximab has an extremely short half-life, platelet aggregation returns to baseline levels within 12–24 hours following discontinuation of therapy. Interestingly, the ISAR-REACT trial demonstrated no additional benefit of abciximab over placebo in the reduction of ischemic complications or mortality. Similarly, among diabetic patients without elevated troponin levels undergoing elective PCI, no difference was observed in primary endpoint events between abciximab and placebo/clopidogrel groups. Conversely, in patients with elevated troponin levels, the incidence of mortality and recurrent ischemic complications was significantly reduced with abciximab. Careful monitoring must be accompanied with the administration of abciximab as bleeding and thrombocytopenia have been observed.

Eptifibatide (Integrilin®, Millenium Pharmaceuticals, Cambridge, MA/Schering-Plough, Kenilworth, NJ) is a cyclic heptapeptide derived from snake venom that contains a KGD (lysine-glycine-aspartic acid) sequence which selectively recognizes αIIbβ3. The IMPACT-II study showed that a single loading dose followed by continuous infusion for 20–24 hours only resulted in 50% αIIbβ3 receptor blockade; thus, limited benefits and efficacy through eptifibatide were observed. The ESPRIT trial, however, which utilized intravenous administration of a double bolus followed by maintenance infusion, significantly reduced the 30 days incidence of death, MI, and target vessel revascularization, establishing the clinical efficacy for this drug. These observations were confirmed in the PURSUIT trial, which showed an absolute reduction in the 30-day incidence of death and MI on eptifibatide. Despite the reduction in mortality, the ACUITY trial also showed an increase incidence of major bleeding in patients with ACS undergoing PCI.

Tirofiban (Aggrastat®, Merck, Whitehouse Station, NJ) is a tyrosine-derivative nonpeptide mimetic reversible inhibitor of αIIbβ3 that specifically and competitively binds to the receptor. Treatment with tirofiban in combination with aspirin and heparin in patients with ACS significantly reduced the 30-day post-treatment incidence of death, MI, or recurrent ischemia. Further, tirofiban was superior for ACS patients recovering from invasive coronary angiography. As for the use of tirofiban as an adjunct to PCI, tirofiban was shown to be inferior to abciximab in the RESTORE and TARGET trials where the incidence of composite death, nonfatal MI, and urgent target vessel revascularization were higher with tirofiban or abciximab at 30 days.

Z4 A5 is a novel αIIbβ3 peptide antagonist that is currently in development. This antagonist has been shown to inhibit platelet-induced aggregation and thrombus formation. Additionally, when Z4 A5 was examined along with heparin and/or aspirin in the rabbit arteriovenous shunt thrombosis model, it was shown to be an effective antithrombotic agent when administered with aspirin. The pharmacodynamics and pharmacokinetics in humans are currently under investigation.

**Additional glycoprotein antagonists**

Additional glycoprotein targets have received a fair amount of attention in the drive to develop novel approaches for antiplatelet intervention. The VWF, a multimeric glycoprotein from the murine human chimera c7E3 Fab, which targets the integrin αIIbβ3, preventing integrin binding to fibrinogen and VWF. Abciximab rapidly binds with high affinity and has a slow rate of dissociation from its target. In addition, abciximab binds with high affinity to α₃ (vitronectin receptor) and low affinity to the leukocyte MAC-1 receptor. Initial intravenous administration enables rapid onset of platelet inhibition. As abciximab has an extremely short half-life, platelet aggregation returns to baseline levels within 12–24 hours following discontinuation of therapy. Interestingly, the ISAR-REACT trial demonstrated no additional benefit of abciximab over placebo in the reduction of ischemic complications or mortality. Similarly, among diabetic patients without elevated troponin levels undergoing elective PCI, no difference was observed in primary endpoint events between abciximab and placebo/clopidogrel groups. Conversely, in patients with elevated troponin levels, the incidence of mortality and recurrent ischemic complications was significantly reduced with abciximab. Careful monitoring must be accompanied with the administration of abciximab as bleeding and thrombocytopenia have been observed.
complex.\textsuperscript{52,63} Vwf also binds to active αIIbβ3 on the platelet surface. Interactions between αIIbβ3 and Vwf contribute to the final, irreversible binding of platelets to the subendothelium and play a leading role in platelet aggregation.\textsuperscript{64} A second target receiving attention as a potential site for antiplatelet therapy is the collagen receptor glycoprotein VI (GPVI). The collagen-GPVI interaction triggers subsequent tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif of the Fc receptor γ chain, activating the Syk kinases pathway, LAT, SLP-76, and phospholipase Cγ2,\textsuperscript{65} resulting in platelet activation or aggregation.

**Vwf antagonists**
AJW200 is an IgG4 humanized monoclonal antibody to Vwf which has been shown to specifically inhibit high-shear-stress-induced platelet aggregation in a concentration-dependent manner in vitro in blood from human volunteers.\textsuperscript{66} ARC1779 (Archemix Corp, San Francisco, CA) is an aptamer-based antagonist. This second generation nuclease-resistant aptamer is conjugated to a 20-Kda polyethylene glycol and binds with high affinity to the active Vwf A1-domain and inhibits Vwf-dependent platelet aggregation.\textsuperscript{67} A Phase II trial demonstrated that continuous infusion of ARC1779 effectively increased platelet counts in critically ill thrombotic thrombocytopenic purpura patients by preventing platelet aggregation and loss of platelets. Cessation of ARC1779 infusion resulted in platelet count reduction and progression of thrombotic thrombocytopenic purpura-related organ damage.\textsuperscript{68} This drug is currently under clinical investigation.

Other Vwf antagonists in clinical development or investigations include ARC15105, ALX-0081 (Ablymax), ALX-0681, and 82D6 A3. ARC15105 is a chemically advanced aptamer with assumed higher affinity to Vwf, but less specific inhibitor of Vwf-dependent platelet aggregation than ARC1779, based on ex-vivo trials.\textsuperscript{69} The preclinical and clinical trials have shown that ALX-0081, a bivalent humanized nanobody that recognizes the Glycoprotein Ib (GPIb) binding site of Vwf, is a potent and safe inhibitor of Vwf-mediated platelet aggregation over a wide range of doses when administered in combination with aspirin, heparin, and clopidogrel. ALX-0081 is currently under investigation in PCI patients in a Phase II trial. 82D6 A3, a monoclonal antibody directed against amino acids Arg-963, Pro-981, Asp-1009, Arg-1016, Ser-1020, Met-1022, and His-1023 of the Vwf A3 domain,\textsuperscript{70} was shown to result in complete inhibition of Vwf binding to collagen during the first 3 days after stent implantation in baboons.\textsuperscript{71} Further trials will need to follow to verify 82D6 A3 efficacy, safety, and tolerability.

**GPVI receptor antagonists**
PR-15 (Revasept\textsuperscript{®}, ABX-CRO/Medifacts GmbH, Goerlitz, Saxony, Germany) is a soluble, dimeric glycoprotein (GPVI)-Fc that has been shown to adhere to exposed collagen in endothelial lesions preventing the binding to platelet GPVI receptors. Collagen-induced human platelet adhesion or plaque formation were significantly reduced with pre-treatment of soluble GPVI-Fc.\textsuperscript{72,73} Similarly, infusion of GPVI-Fc was shown to virtually abolish stable arrest and aggregation of platelets following vascular injury in mice.\textsuperscript{69} Subsequently, a Phase I clinical trial demonstrated that intravenous administration of PR-15 is safe and well tolerated by healthy volunteers.\textsuperscript{74}

DZ-697b is an orally active collagen and ristocetin inhibitor. Safety and efficacy have been assessed in a Phase I trial which showed potential benefits such that bleeding time was substantially shortened compared with clopidogrel treatment.\textsuperscript{75} DZ-697b is currently under clinical investigation.

**GPIb receptor antagonists**
Novel targets still under investigation include h6B4-Fab, GPGP-290, and SZ2. h6B4-Fab is a murine monoclonal antibody derived from the humanized Fab fragment of 6B4 targeting GPIbα and neutralizes the binding site of the Vwf A1 domain.\textsuperscript{76,77} 6B4 has been shown to inhibit platelet adhesion by competing with Vwf for binding to GPIbα under high-shear conditions. Moreover, preliminary data show 6B4 has no effect on platelet count or bleeding times in vivo in baboons, but does- and time-dependently inhibited ristocetin-induced platelet aggregation.\textsuperscript{78} GPG-290 is a recombinant, chimeric antibody purified from Chinese hamster ovary cell culture that contains the amino-terminal 290 amino acids of GPIbα linked to the human IgG1. GPG-290 treated dogs were shown to exhibit prolonged bleeding compared with the clopidogrel-treated control, despite the prevention of coronary artery thrombosis.\textsuperscript{79} SZ2, a monoclonal antibody developed against GPIbα, has also been shown to inhibit both ristocetin- and botrocetin-induced platelet aggregation in vitro.\textsuperscript{80} Preclinical investigations are still underway to determine the in-vivo efficacy of SZ2.

**Phosphodiesterase antagonists**
Platelets express three phosphodiesterase (PDE) isoenzymes, PDE 2, 3, and 5. PDEs regulate the levels of 3′,5′-cyclic adenosine monophosphate (Camp) and 3′,5′-cyclic guanosine monophosphate (Cgmp) by catalyzing the hydrolysis of Camp and Cgmp to inactive 5′-AMP and 5′-GMP, respectively.\textsuperscript{81} Platelet activation relies on degradation of Camp
and Cgmp; hence regulating these secondary messengers is fundamental in regulating platelet activation and thrombosis.

Cilostazol (Pletal®, Otsuka Pharmaceutical Co, Tokyo, Kapan) is a type III PDE (PDE3) selective oral inhibitor. Liu and colleagues have shown that cilostazol enhances the interstitial concentration of adenosine in several in-vitro and in-vivo models by inhibiting adenosine uptake. This in turn stimulates A2 receptors, which further increases Camp levels. As a result, platelet-induced aggregation is reversibly inhibited by cilostazol. Cilostazol is extensively metabolized by CYP3 A4, while CYP2C19 is also shown to have a minor role in cilostazol metabolism. Cilostazol is safe and effective in reducing the incidence of repeated revascularization after PCI and risk of restenosis; however, this drug does not show superiority in reducing the primary composite endpoints of adverse cardiovascular events after drug-elution stent implantation. Despite the functional implications of adjunctive treatment with cilostazol compared with standard aspirin and clopidogrel treatment, as shown in the OPTIMUS-2 study, the accompanied side effects (headaches, gastrointestinal symptoms, and skin rash) often lead to the discontinuation of the drug.

Dipyridamole (Aggrenox®, Boehringer Ingelheim, Ingelheim, Germany) is a pyridopyrimidine derivative with both antiplatelet and vasodilator properties. Similar to cilostazol, dipyridamole inhibits cyclic nucleotide phosphodiesterase and blocks adenosine uptake, which results in increased Camp. The ESPS-2 and ESPRIT trials showed that dual treatment of dipyridamole and aspirin reduced risk of stroke or death by 37% compared with aspirin alone. Based on the ESPRIT and ESPS-2 trials, dipyridamole has been FDA approved for stroke prevention.

**Thromboxane A2 receptor antagonists**

Platelets express the thromboxane receptor α (TPα), a GPCR that is coupled to Gq and G12/13 and signals platelet activation through a number of intracellular pathways which converge to reinforce primary platelet activation through thrombin or collagen.

S18886 (terutroban) is an oral reversible inhibitor of TPα. In preclinical studies, S18886 dose-dependently prolonged occlusive thrombus formation in animal models, but did not alter the size of the myocardial infarct size in the ischemia-perfusion model. S18886 and clopidogrel were effective in preventing occlusive thrombus formation with a moderate increase in bleeding time. Subsequently, however, in the Phase III clinical trial (PERFORM), S18886 did not meet the predefined criteria for noninferiority since S18886 and aspirin had similar rates of protection without safety advantages for S18886.

Z-335 ((+/-)-sodium[2-(4-chlorophenylsulfonyl-amino-methyl)indan-5-yl]acetate monohydrate) is an oral TPα antagonist that has previously been shown to dose-dependently inhibit the specific binding of [3H]SQ-29548 (TPα inhibitor) to human and guinea pig platelet membranes. In healthy male Japanese volunteers, Z-335 inhibited U46619-induced platelet aggregation within 2 hours of administration.

BM-573, another investigational inhibitor that targets TPα, has been shown to halt the progression of atherosclerosis in low-density lipoprotein receptor deficient mice. Preclinical models have shown that arachidonic acid-induced aggregation is completely inhibited in the presence of BM-573 and clinical studies on this compound are currently ongoing.

**Thrombin receptor antagonists**

Thrombin activates human platelets via two protease activated receptors (PARs), PAR1 and PAR4. PAR activation leads to a diverse range of pro-thrombotic signaling events mediated through Gq and G12/13, and possibly G5, resulting in phospholipase β activation, Rho activation, and adenyl cyclase inhibition, respectively. PAR activation requires thrombin cleavage of the amino terminus of the receptor, revealing a tethered ligand. While it has been challenging to develop an inhibitor that can directly compete with the endogenous tethered ligand, development of PAR1 inhibitors as a therapeutic target to minimize uncontrolled platelet activation has recently been investigated.

SCH 530348 (Vorapaxar®, Merck and Co, Whitehouse Station, NJ) is an orally active synthetic analog of himbacine that competitively binds with high affinity to the PAR1. Previous in-vitro assays show SCH 530348 inhibited thrombin- and thrombin receptor activating peptide-induced platelet aggregation, without affecting the aggregation induced by ADP, U46619, or collagen. In addition, SCH 530348 did not affect the prothrombin and activated partial thromboplastin time, suggesting that bleeding time may not be increased. Pre-clinically, cynomolgus monkeys treated with SCH 530348 alone or in addition with aspirin and clopidogrel, showed no increase in bleeding times. The TRA-PCI study verified that addition of SCH 530348 to standard antiplatelet therapy (aspirin and clopidogrel) was not associated with increases in thrombolysis in MI (TIMI)
or bleeding compared with the control group.\textsuperscript{101} The Phase III clinical trials TRA-CER and TRA \textsuperscript{2}P-TIMI, which sought to assess the impact of vorapaxar on cardiovascular death, MI, stroke, and recurrent vascular events in patients with established coronary, cerebral, or peripheral atherosclerosis\textsuperscript{102} failed due to unforeseen intracranial bleeding.\textsuperscript{102}

Preclinical trials showed that oral administration of the PAR1 antagonist, E5555 (Atoanaxar\textsuperscript{®}, Eisai Co Ltd, Tokyo, Japan), significantly prolonged bleeding times in guinea pigs.\textsuperscript{103} Further, PECAM-1, active c\alpha\beta\beta3, GPIIb, thrombospondin, and vitronectin expression were significantly reduced by E5555 in whole blood flow cytometry. Clinical studies have shown that E5555 attenuated thrombin-induced but not ADP-induced platelet aggregation.\textsuperscript{104,105}

Additional PAR-1 antagonists SCH 205831 and SCH 602539 are still under investigation. Preliminary data show SCH 205831 derived from himbacin inhibited platelet deposition in baboons with arteriovenous-shunt thrombosis. Similarly, SCH 602539 inhibited thrombosis in a dose-dependent manner in the Folts model of thrombosis in anesthetized cynomolgus monkeys.\textsuperscript{106} These compounds continue to be developed in preclinical models.

**Conclusion**

Significant progress has been made in advancing our understanding of how platelet activation directly regulates thrombus formation in the vessel leading to occlusive thrombi and stroke. However, a continued need for the development of new antiplatelet therapies exists as the risk for MI, stroke, and death, remain a persistent problem for individuals suffering from cardiovascular disease. Further, while aspirin continues to be the first line of pharmacological intervention in antiplatelet therapy, the risk of bleeding is significantly exacerbated by its irreversible action coupled to the additional regimen of dual therapy often employed to minimize thrombotic events. In hopes of reducing prolonged bleeding or myocardial infarct events, newer compounds continue to be developed to target alternative sites in the platelet. The successful implementation of these strategies may significantly reduce the morbidity and mortality in cardiovascular disease due to unwanted platelet activation as well as excessive bleeding due to traditional approaches. Even with the newer antiplatelet drugs entering the market in the near future, we are faced with the realization that activation of the platelet involves an increasingly complex signaling network. Hence, new frontiers will need to be explored which will take advantage of this signaling to reveal novel therapeutic targets with diminished off-target effects.

**Acknowledgments**

This work was supported in part by the National Institutes of Health National Heart, Lung, and Blood Institutes grant HL089457 (MH).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


38. Yeung and Holinstat


